ADCT (ADC Therapeutics) operates as a clinical and commercial-stage biotechnology firm focused on oncology. The company designs, develops, and delivers advanced antibody-drug conjugates engineered to harness human monoclonal antibodies that bind selectively to tumor-associated antigens. By attaching potent cytotoxic agents to these antibodies, the company's therapies seek to eradicate cancer cells effectively while sparing healthy organs from the widespread toxicity associated with conventional systemic chemotherapy regimens.